91 related articles for article (PubMed ID: 29981438)
1. Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy.
Kinsey E; Ajazi E; Wang X; Johnston MAM; Crawford J
J Thorac Oncol; 2018 Sep; 13(9):1294-1301. PubMed ID: 29981438
[TBL] [Abstract][Full Text] [Related]
2. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
4. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
[TBL] [Abstract][Full Text] [Related]
5. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
6. Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer.
Morio K; Minami T; Sozu T; Niki K; Kijima T; Uejima E; Morio K
Chemotherapy; 2016; 61(5):256-61. PubMed ID: 27031828
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the Efficacy and Safety of Platinum Doublet Re-Challenge Chemotherapy in Patients with Recurrent Advanced Non-Small Cell Lung Cancer].
Mori A; Hirose T; Tamura A; Kusaka K; Matsui H; Ohta K
Gan To Kagaku Ryoho; 2016 Jun; 43(6):723-6. PubMed ID: 27306808
[TBL] [Abstract][Full Text] [Related]
10. Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
Rigas JR
Oncologist; 2004; 9 Suppl 2():16-23. PubMed ID: 15161987
[TBL] [Abstract][Full Text] [Related]
11. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
Ramsden K; Laskin J; Ho C
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
17. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.
Eton DT; Fairclough DL; Cella D; Yount SE; Bonomi P; Johnson DH;
J Clin Oncol; 2003 Apr; 21(8):1536-43. PubMed ID: 12697878
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
Vansteenkiste J; Pirker R; Massuti B; Barata F; Font A; Fiegl M; Siena S; Gateley J; Tomita D; Colowick AB; Musil J;
J Natl Cancer Inst; 2002 Aug; 94(16):1211-20. PubMed ID: 12189224
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
20. Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.
Wang J; Li G; Yu L; Mo T; Wu Q; Zhou Z
J Ethnopharmacol; 2018 Jul; 221():137-150. PubMed ID: 29655852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]